Product Description
Mechanisms of Action: 5-HT1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amarantus BioScience Holdings
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dyskinesias|Parkinson's Disease|Cognitive Dysfunction|Schizophrenia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02439125 |
AMBS-ELTO-201 | P2 |
Unknown status |
Parkinson's Disease|Dyskinesias |
2017-06-01 |
2019-03-20 |
Treatments |
|
2015-000373-13 |
2015-000373-13 | P2 |
Temporarily not available |
Parkinson's Disease |
2016-08-18 |
2022-03-13 |
Treatments |
|
NCT01266174 |
PGI12004 | P2 |
Completed |
Cognitive Dysfunction|Schizophrenia |
2012-09-01 |
2019-03-19 |
||
2009-015928-28 |
ELTODYS09 | P2 |
Terminated |
Dyskinesias|Parkinson's Disease |
2012-02-17 |
2025-06-26 |
Treatments |